Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: J Oral Pathol Med. 2011 Nov 18;41(4):309–314. doi: 10.1111/j.1600-0714.2011.01117.x

Table 3.

Prevalence of oral HPV-16 in each subject group

Group Prevalence
HPV-16 E6 p-value HPV-16 E7 p-value
Non-HIV (n=20) 9 (49%) 0.024 8 (40%) 0.108
HIV (n=49) 37 (76%) 31 (63%)
HIV-no ART (n=12) 8 (67%) 0.454 7 (58%) 0.738
HIV-ART (n=37) 29 (78%) 24 (65%)
Short-term ART (n=19) 14 (74%) 0.692 15 (79%) 0.091
Long-term ART (n=18) 15 (83%) 9 (50%)

ART, antiretroviral therapy; HPV, human papillomavirus.